• Dadifer@lemmy.world
    link
    fedilink
    English
    arrow-up
    10
    ·
    5 hours ago

    I got to say, I’m not convinced. All this really shows is that bisoprolol does not trigger the primary outcome (85% use), which is a composite of 3 things - death from any cause, reinfarction and hospitalization for heart failure. I don’t think I’ve used bisoprolol a single time in my career.

    Also, I need to recalculate the power, because they say themselves the event rate wasn’t any where near what they thought it would be. So this study was severely underpowered, which is ironic since the primary event rate was 7.4% and 7.2%. So yes, maybe you don’t want to have a power to distinguish between a 7.4 and 7.2% event rate, but it’s also very possible that actual mortality is getting lost in the noise with the composite primary end point.

      • fafferlicious@lemmy.world
        link
        fedilink
        English
        arrow-up
        1
        ·
        23 minutes ago

        Power is a function of the size of the difference you’re testing for. Idk how to really calculate it accurately, but this site would suggest to discriminate between 7.2% and 7.4% you’d need over 300,000 participants

        I’m kind of skeptical of that, but I don’t know enough about clinical trials to know that.